Premier Research Announces Appointment of Eeva-Kaarina Koskelo
News Mar 02, 2012
Premier Research Group has announced the appointment of Dr. Eeva-Kaarina Koskelo to the position of Executive Director, Clinical Development Services, Pediatrics.
In this position, Dr. Koskelo will play a principal role in the strategic planning and execution of pediatric studies at Premier Research.
She joins an accomplished pediatrics team in the United States and Europe that provides full-service clinical trial management and regulatory support for pediatric trials.
“Throughout her career, Eeva-Kaarina has been a recognized leader in pediatric clinical research and will support our customers with their pediatric study needs from strategy development through to study execution,” said Dr. Sue Stansfield, Executive VP, Clinical Development.
Dr. Stansfield continued, “She brings extensive, global pediatric experience and offers depth of knowledge across multiple therapeutic areas, age groups, study designs and clinical settings.”
Dr. Koskelo has more than 20 years of experience in the academic, biotechnology and pharmaceutical arenas including 15 years of drug development experience.
Her impressive track record includes hands on global program management of projects in Europe, North America, Latin America, Africa, India, Southeast Asia, and Australia with a specific focus on pediatric studies conducted in compliance with FDA written requests and other regulatory authorities.
Additionally, she has held residencies in Finland, US and South Africa thus gaining a strong multi cultural background and understanding of various cultures.
Her CRO experience includes positions of increasing responsibility ending at an executive level at Quintiles, Inc. and Encorium Oy, Ltd.
Dr. Koskelo holds a PhD in clinical nutrition with publications in protein-energy malnutrition in children with cancer and a Master’s degree in nutrition from the University of Helsinki as well as an Executive MBA from the Helsinki School of Economics, Finland.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE